China Medical System Subsidiary Enrolls First Patient in Vitiligo Phase III Trial
What happened
Dermavon Holdings Limited, a subsidiary of China Medical System Holdings Limited, enrolled the first patient in a China Phase III clinical trial for Povorcitinib Phosphate Tablets on November 19, 2026. The study is a multi-center, randomized, double-blind, placebo-controlled trial evaluating the drug's efficacy and safety for non-segmental vitiligo in Chinese adults. The trial is planned to take place at approximately 44 clinical research centers across China, aiming to enroll about 174 patients.
From pr-inside.com
Why it matters
The trial represents a significant step in the clinical evaluation of Povorcitinib, an innovative oral JAK1 inhibitor. Dermavon is also applying for a separate listing on The Stock Exchange of Hong Kong Limited, linking the company's future to the financial markets in Hong Kong.
From pr-inside.com
Who's involved
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- CMSSpeculative
China Medical System Holdings Limited might see increased investment interest due to the progress of its subsidiary's drug development.